The avacopan story, stronger again: (recall: avacopan targets C5aR) endogenous anti-C5aR1 in GPA inversely correlates with dx activity, relapse questions, via chair @philseo: What happens to anti-C5aR1 with Rx? Does this influence therapeutic strategy? #ACR20 ABST2050 @RheumNow https://t.co/g4JfjQal8R

Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038. @rheumnow @DrPujaMehta1 #ACR20 Abstr#L06 #ACRbest https://t.co/MTuH0sAuWt

Novel predictors of early mortality in a cohort of GCA pts from Portugal: 🚩Older age at dx 🚩Tongue claudication 🚩Prior tx w/ anticoag BP treatment at dx - predictor of early survival. @RheumNow #ACR20 abs1935 https://t.co/TGJNnZ8vTQ

Dr Benard reports an SLR and meta-analysis of 27 studies comparing 2 rituximab regimes in AAV. 375mg x4 and 1000mg x2 equivalent. Remission in 91% vs 85%. Similar adverse event rates @rheumnow #ACR20 Abstr#2048 https://t.co/I0feVuZ8iy

Dr Sanchez-Bilbao reports a study of 30 patients with LV GCA. Despite clinical remission with tocilizumab ongoing vascular inflammatory activity identified by PET in 70%. Significant implications for risk of tocilizumab withdrawal. @rheumnow #ACR20 Abstr#1921 https://t.co/f1isidSypn

Tocilizumab in GCA: what happens in the vessels? Supporting excellent work @KQuinnRheum @petercgrayson earlier at #ACR20, LV-GCA data from Blanco/Gonzalez-Gay et al. Aorta still hot at 10.8±3.7 mo. in LV-GCA on TCZ, clinical remission ≠ PET remission #ACR20 ABST1921 @RheumNow https://t.co/ngBVL4rop8

High #bloodpressure, jaw claudication and temporal artery abnormalities on palpation associated with increased risk of serious ischaemic events in #GCA, incl visual loss and #CVA. #MSK symptoms including PMR are protective. Abs#1944 #ACR20 @RheumNow https://t.co/sTeql8py9r

• Predictors of Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis…

SLR of frequency of visual ischaemia (VI) in relapse & follow-up of GCA -VI >4weeks after GCA diagnosis is uncommon -VI occurs in up to 3% patients with at least one relapse -VI reported 3.5x more in RCTs vs retrospective studies Abs#1929 #ACR20 @RheumNow https://t.co/OztFRZ9VHc

• Visual Ischemia During Relapse and Follow-up of Giant Cell Arteritis: A Systema…